In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance (Q40277481)

19 September 2017

title

In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance (English)

1 reference

19 September 2017

Sophie Le Pogam

1

1 reference

19 September 2017

Wen-Rong Jiang

2

1 reference

19 September 2017

Vincent Leveque

3

1 reference

19 September 2017

Sonal Rajyaguru

4

1 reference

19 September 2017

Han Ma

5

1 reference

19 September 2017

Hyunsoon Kang

6

1 reference

19 September 2017

Sharon Jiang

7

1 reference

19 September 2017

Margaret Singer

8

1 reference

19 September 2017

Samir Ali

9

1 reference

19 September 2017

Klaus Klumpp

10

1 reference

19 September 2017

Dave Smith

11

1 reference

19 September 2017

Julian Symons

12

1 reference

19 September 2017

Nick Cammack

13

1 reference

19 September 2017

Isabel Nájera

14

1 reference

19 September 2017

language of work or name

English

0 references

publication date

19 May 2006

1 reference

19 September 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

Virology

1 reference

19 September 2017

volume

351

1 reference

19 September 2017

issue

2

1 reference

19 September 2017

page(s)

349-359

1 reference

Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Replication Studies Using Genotype 1a Subgenomic Hepatitis C Virus Replicons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Viral and Cellular Determinants of Hepatitis C Virus RNA Replication in Cell Culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Resistance Profile of a Hepatitis C Virus RNA-Dependent RNA Polymerase Benzothiadiazine Inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Nm 283, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Characterization of cell lines carrying self-replicating hepatitis C virus RNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

A three-dimensional model to analyze drug-drug interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Genetic diversity and evolution of hepatitis C virus--15 years on

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Secondary structure and hybridization accessibility of hepatitis C virus 3'-terminal sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Epidemiology of hepatitis C: geographic differences and temporal trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.045

10.1016/J.VIROL.2006.03.045

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference